26 May 2008 - Czech nutritional and pharmaceutical supplement firm Walmark has announced it has signed a contract with Bristol-Myers Squibb whereby Walmark will acquire 5 products from Bristol-Myer's pharmaceutical portfolio.
Walmark will also be authorised to produce and distribute the products in the Czech Republic, Slovakia, Hungary and Poland.
The deal is seen as the company’s new strategic goal to extend its pharmaceutical portfolio.
Meanwhile, the Czech firm claims it also intends to become one of three biggest manufacturers of food supplements in Europe – and this target is expected to be reached by 2012. Moreover, the company expects to become the leader in this market by 2017, it said in a statement.
“Walmark also aims to enter the market of sports nutrition more vigorously and to become number one in this segment in Central Europe by 2012”, said the Czech nutritional supplement firm.
Walmark was established in 1990. In 2001 the company was transformed from a limited liability company to a joint-stock company with 8 shareholders at the present time – Czech individuals. Presently the company has one of the most modern pharmaceutical manufacturing plants in the Czech Republic.
The company is the biggest manufacturer of nutritional supplements in Central and Eastern Europe. It has subsidiaries in 9 European countries (Slovakia, Poland, Hungary, Romania, the Ukraine, Lithuania, Latvia, France) and its products are exported into more than 20 countries of the world.